论文部分内容阅读
目的探讨紫杉醇同步后程三维适形放疗治疗Ⅲ期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法应用随机数字表法将2008年3月至2012年3月收治的90例Ⅲ期非小细胞肺癌患者随机分为对照组和观察组,每组各45例,比较两组患者的临床疗效和不良反应发生率。结果观察组患者的治疗总有效率(82.2%)明显高于对照组(57.8%),差异有统计学意义(P<0.05);不良反应发生率两组差异无统计学意义(P>0.05)。结论紫杉醇同步后程三维适形放疗治疗Ⅲ期非小细胞肺癌疗效确切,安全高效,不良反应少。
Objective To investigate the clinical efficacy and safety of paclitaxel synchronized late course three-dimensional conformal radiotherapy for stage Ⅲ non-small cell lung cancer (NSCLC). Methods Ninety patients with stage Ⅲ non-small cell lung cancer who were treated from March 2008 to March 2012 were randomly divided into control group and observation group with 45 cases in each group. The clinical efficacy and Adverse reaction rate. Results The total effective rate (82.2%) in observation group was significantly higher than that in control group (57.8%), the difference was statistically significant (P <0.05). The incidence of adverse reactions was no significant difference between the two groups (P> 0.05) . Conclusion Paclitaxel synchronized posterior longitudinal three-dimensional conformal radiotherapy for the treatment of stage Ⅲ non-small cell lung cancer is effective, safe and efficient, with fewer adverse reactions.